Any current/future new fundraising through debt or equity?

The transcript provided does not explicitly mention any current or planned fundraising activities through debt or equity. The company is undertaking a significant capex plan of INR 1,100 crores between FY '24 and FY '28, split evenly between Essentials and Specialties. The management mentioned leveraging an "un-leveraged balance sheet" indicating capacity for investment but did not specify plans to raise new funds. They focused on ongoing projects and operational expansions funded within existing resources. No direct references to raising capital through debt or equity financing were made duri

Any current/future capex/capital investment/strategic investment?

Laxmi Organic has planned a total capex of INR 1,100 crores from FY '24 to FY '28, evenly split between Essentials (INR 550 crores) and Specialties (INR 550 crores). A new world-scale n-butyl acetate plant (70 KT capacity) is being set up at Dahej with a capex of about INR 90 crores, serving as a 100% import substitute product. A world-scale ethyl acetate line is planned at Lote, Maharashtra, with a capex of INR 90 crores, leveraging government mega status incentives. The Lote facility has additional land available for up to INR 400 crores more capex, mainly for expansion in fluorine verticals

Future growth expectations in sales/revenue/volumes?

Laxmi Organic aims to double revenues from FY '24 to FY '28, targeting INR 200 crore peak revenue by FY '27 in Specialty products. Volume growth in Essential chemicals strong with 20% year-on-year increase and 16% sequential growth. Expected continued double-digit top-line and volume growth in Q3 FY '25, with predictability and confidence building internally and with customers. New capacity expansions such as the 70 KT/annum n-butyl acetate plant at Dahej to drive import substitution and market expansion. Specialty business to contribute 10-15% of peak revenues by Q4 FY '25, increasing to 40-6

Future growth expectations in earnings/operating earnings/profits/EPS?

Laxmi Organic delivered double-digit top-line, volume, and bottom-line growth in Q2 FY '25 and H1 FY '25 despite market challenges, signaling strong operational momentum. The company aims to sustain year-on-year growth into Q3 FY '25 as per management's guidance. EBITDA for Q2 (~INR 75 crores) is targeted as a sustainable baseline, with ambitions to increase via pricing improvements or additional capacity expansions. Their Specialty chemicals division targets robust EBITDA margins of 20%-25%, independent of market cycles, supporting steady profit growth. Capex of INR 1,100 crores (equally spli

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders details. However, the company discussed operational progress and commercial production plans, especially: - Fluoro intermediate site focusing on scaling plant and starting revenue generation in the second half of FY '25. - Dahej project on track to receive pending regulatory approvals and progressing on time and budget. Management expressed confidence in continued year-on-year growth in Q3 FY '25, implying steady order inflow. Customer approvals have increased for Fluorochemicals products (16 ou

Laxmi OrganicQ2 FY25Chemicals & Petrochemicals

Laxmi Organic Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹181P/E: 40.1Market Cap: ₹5.0K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Laxmi Organic aims to double revenues from FY '24 to FY '28, targeting INR 200 crore peak revenue by FY '27 in Specialty products.
Volume growth in Essential chemicals strong with 20% year-on-year increase and 16% sequential growth.
Expected continued double-digit top-line and volume growth in Q3 FY '25, with predictability and confidence building internally and with customers.
New capacity expansions such as the 70 KT/annum n-butyl acetate plant at Dahej to drive import substitution and market expansion.
Specialty business to contribute 10-15% of peak revenues by Q4 FY '25, increasing to 40-60% in the next financial year.
Focus on diversifying industry applications (pharma, agro, pigments, personal care) to ensure stability and growth.
Operational excellence and cost improvement initiatives support sustainable EBITDA growth around INR 75 crores per quarter.

Margin guidance

Category 3

Laxmi Organic delivered double-digit top-line, volume, and bottom-line growth in Q2 FY '25 and H1 FY '25 despite market challenges, signaling strong operational momentum.
The company aims to sustain year-on-year growth into Q3 FY '25 as per management's guidance.
EBITDA for Q2 (~INR 75 crores) is targeted as a sustainable baseline, with ambitions to increase via pricing improvements or additional capacity expansions.
Their Specialty chemicals division targets robust EBITDA margins of 20%-25%, independent of market cycles, supporting steady profit growth.
Capex of INR 1,100 crores (equally split between Essentials and Specialties) is expected to double revenues and improve ROCE to 20% by FY '28.
New product launches, capacity expansions (e.g., ethyl acetate, butyl acetate), and expansion into new industries are key drivers.
The Fluoro-intermediate plant scaling and upcoming Dahej approvals will contribute future revenue.
Diversification across geographies and industries adds to earnings visibility and growth stability.

See what Laxmi Organic management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript provided does not explicitly mention any current or planned fundraising activities through debt or equity.
The company is undertaking a significant capex plan of INR 1,100 crores between FY '24 and FY '28, split evenly between Essentials and Specialties.
The management mentioned leveraging an "un-leveraged balance sheet" indicating capacity for investment but did not specify plans to raise new funds.
They focused on ongoing projects and operational expansions funded within existing resources.
No direct references to raising capital through debt or equity financing were made during the Q2 FY '25 earnings call.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders details.
However, the company discussed operational progress and commercial production plans, especially:
- Fluoro intermediate site focusing on scaling plant and starting revenue generation in the second half of FY '25.
- Dahej project on track to receive pending regulatory approvals and progressing on time and budget.
Management expressed confidence in continued year-on-year growth in Q3 FY '25, implying steady order inflow.
Customer approvals have increased for Fluorochemicals products (16 out of 20 customers approved), indicating potential forthcoming orders.
The specialty vertical sees expanding products and customers, supporting a positive demand outlook.
No specific numeric or timeline details on the order book or pending orders provided in this transcript.

See what Laxmi Organic management said on order book — free account, 30 seconds.

Capex plans

Yes

Laxmi Organic has planned a total capex of INR 1,100 crores from FY '24 to FY '28, evenly split between Essentials (INR 550 crores) and Specialties (INR 550 crores).
A new world-scale n-butyl acetate plant (70 KT capacity) is being set up at Dahej with a capex of about INR 90 crores, serving as a 100% import substitute product.
A world-scale ethyl acetate line is planned at Lote, Maharashtra, with a capex of INR 90 crores, leveraging government mega status incentives.
The Lote facility has additional land available for up to INR 400 crores more capex, mainly for expansion in fluorine verticals and fluoro-intermediates.
Specialty vertical investments focus on diketene derivatives, fluorination, and broadening product baskets, targeting 10%-15% of peak revenues by FY '25 and 40%-60% by FY '26, reaching full peak in FY '27.

Track Laxmi Organic — get its next earnings analysis in your feed

How does Laxmi Organic rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisLaxmi Organic

Rev 3Mar 3

See where Laxmi Organic sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Laxmi Organic rank in Chemicals & Petrochemicals?

Compare Laxmi Organic against every Chemicals & Petrochemicals company (Q2 FY25) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Laxmi Organic Industries Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Prasol Chemicals Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank
Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
Vipul Organics Ltd (Q1 FY27)
Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…
Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Laxmi Organic Q2 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Laxmi Organic rank in Chemicals & Petrochemicals?

Continue your research

What Laxmi Organic Industries Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season